Meta AnalysisID 5680
五种常用中药方剂治疗溃疡性结肠炎的网状Meta分析
CRD42022360996
The aim of this meta-analysis of randomized controlled trials is to evaluate the clinical efficacy and safety of five traditional Chinese herbal formulas, Baitouweng Decoction, Shenling Baizhu Powder, Xilei Powder, Shaoy
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5680
- Evidence Id
- 14238
- Core Evidence Id
- 14238
- Source Meta Analysis Id
- 5660
- Herb2 Meta Analysis Id
- HBMA005660
- Crd Id
- CRD42022360996
- Title
- A network meta-analysis of five commonly used traditional Chinese medicine prescriptions in the treatment of ulcerative colitis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the clinical efficacy and safety of five traditional Chinese herbal formulas, Baitouweng Decoction, Shenling Baizhu Powder, Xilei Powder, Shaoyao Decoction, and Changyanningin the adjuvant treatment of ulcerative colitis (UC).
- Study Type Included
- Randomized controlled trials (RCTs) will be included.
- Condition Being Studied
- The etiology of UC is not yet clear, and the course of the disease is long and prone to recurrence.Currently, aminosalicylates, sulfasalazine and corticosteroids, immunosuppressants and monoclonal antibodies are commonly used in clinical treatment of UC.However, long-term or high-dose use of these drugs can cause serious adverse reactions to the body.For examples increased abdominal pain, kidney damage, liver toxicity, or blood disorders.In recent years, basic research and clinical research on the adjuvant treatment of UC with traditional Chinese medicine formulations have achieved remarkable curative effects.It can not only improve the clinical efficacy, repair the state of intestinal mucosa, but also improve the body's own immunity to achieve the effect of prevention and recurrence.
- Participant
- inclusion criteria:The patients conformed to the Consensus Opinions on the Diagnosis and Treatment of Inflammatory Bowel Disease (2018 Beijing) [7], and the age, gender, and race of the patients were not limited. exclusion criteria:①Ulcerative colitis with serious complications②Severe underlying diseases, mental diseases and patients with allergies to the drugs involved in this study③ Animal experiments or literature review④ Unable to obtain the full text and duplicate publications.
- Animal
- Human Disease Modelled
- Intervention
- The control intervention was mesalazine or mesalazine plus placebo;On the basis of the control group, the experimental group was treated with traditional Chinese medicine.The route of administration is oral or enema.
- Comparator Control
- The control intervention was mesalazine or mesalazine plus placebo;On the basis of the control group, the experimental group was treated with traditional Chinese medicine.The route of administration is oral or enema.
- Main Outcome
- 1.Clinical efficacy 2.Colonoscopy 3.Serum inflammatory factor levels Measures of effect 1.Clinical efficacy(odds ratios, OR) 2.Colonoscopy (mean different, MD)3.tumor necrosis factor (TNF)(mean different, MD)
- Outcome Measure
- Additional Outcome
- 4.IBDQ scale for quality of life evaluation 5.Recurrence rate Measures of effect 4.IBDQ scale for quality of life evaluation(mean different, MD) 5.Recurrence rate (odds ratios, OR)
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- China; Colitis, Ulcerative; Humans; Medicine, Chinese Traditional; Network Meta-Analysis; Powders; Prescriptions; Randomized Controlled Trials as Topic; Treatment Outcome
- Contact
- Zhao Zhihui [email protected]
- Organisational Affiliation
- Beijing University of Chinese Medicine
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-09-26
- Registration Date
- 2022-10-07
- Anticipated Start Date
- 2022-09-19
- Anticipated Completion Date
- 2022-11-30
- Title Cn
- 五种常用中药方剂治疗溃疡性结肠炎的网状Meta分析
- Title En
- A network meta-analysis of five commonly used traditional Chinese medicine prescriptions in the treatment of ulcerative colitis
- Bilingual Status
- complete